What is 10x Genomics?
10x Genomics is a single-cell and spatial biology tools company serving enterprise, public-sector, commercial, consumer, or regulated-market customers.
- Category
- Single-cell and spatial biology tools
- Headquarters
- Pleasanton, CA
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: TXG
What is 10x Genomics?
10x Genomics is a single-cell and spatial biology tools company headquartered in Pleasanton, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
10x Genomics is a single-cell and spatial biology tools company headquartered in Pleasanton, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, 10x Genomics should be mapped as a scaled public-company account rather than an early-stage company. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does 10x Genomics offer?
10x Genomics's profile centers on Chromium platform, Visium spatial, Xenium in situ, Single-cell analysis.
- Chromium platform· Single-cell and spatial biology tools
- Visium spatial· Single-cell and spatial biology tools
- Xenium in situ· Single-cell and spatial biology tools
- Single-cell analysis· Single-cell and spatial biology tools
- Consumables· Single-cell and spatial biology tools
- Bioinformatics· Single-cell and spatial biology tools
How does 10x Genomics make money?
10x Genomics makes money through commercial activity tied to single-cell and spatial biology tools.
10x Genomics monetizes through the model common to single-cell and spatial biology tools: product sales, recurring services, subscriptions, contracts, distribution, transaction volume, underwriting, regulated utility revenue, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, uptime, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads 10x Genomics?
10x Genomics's named executives should be verified on the official leadership or investor-relations page before outreach.
- 10x Genomics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- 10x Genomics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- 10x Genomics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact 10x Genomics's leadership?
10x Genomics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.10xgenomics.com- 10x Genomics investor relationsInvestor relations / corporate contactcontact via https://www.10xgenomics.com
- 10x Genomics media relationsMedia or communications contact routecontact via https://www.10xgenomics.com
How is 10x Genomics funded?
10x Genomics's current status is Public company; Nasdaq: TXG.
10x Genomics's capital profile is best understood through its current public-company status: Public company; Nasdaq: TXG. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capex plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did 10x Genomics get here?
10x Genomics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- Founding10x Genomics is foundedThe company begins building in single-cell and spatial biology tools.
- Scale-upCommercial footprint expands10x Genomics broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: TXGPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are 10x Genomics's competitors?
10x Genomics competes with larger incumbents and focused specialists in single-cell and spatial biology tools.
- Thermo Fisher ScientificLife sciences tools, diagnostics, and services incumbent.
- DanaherLife sciences and diagnostics platform company.
- MedtronicGlobal medical technology competitor.
- PfizerLarge pharmaceutical company with global commercial reach.
- IQVIAHealthcare data and clinical research platform competitor.
10x Genomics — frequently asked questions
